1. Martin, C. J., Alcock, N., Hiom, S., & Birchall, J. C. (2017). Development and Evaluation of Topical Gabapentin Formulations. Pharmaceutics, 9(3), 31. https://doi.org/10.3390/pharmaceutics9030031
  2. Lawson, E., Singla, P., Adler, J., Argoff, C. E., Bettinger, J. J., Bhaskar, A., Clarke, H., Eidelman, A., Hirani, S., Hooten, W. M., Tishler, J., Wallace, M. S., & Barreveld, A. M. (2025). Topical analgesics for neuropathic pain: An Evidence-Informed guide for the practicing clinician. Pain medicine (Malden, Mass.), pnaf130. Advance online publication. https://doi.org/10.1093/pm/pnaf130
  3. Hiom, S., Patel, G. K., Newcombe, R. G., Khot, S., & Martin, C. (2015). Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin. The British journal of dermatology, 173(1), 300–302. https://doi.org/10.1111/bjd.13624
  4. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Assessment of the Available Scientific Data Regarding the Safety and Effectiveness of Ingredients Used in Compounded Topical Pain Creams; Jackson LM, Schwinn DA, editors. Washington (DC): National Academies Press (US); 2020 May 13.
  5. Vadurri V. (2008). Topical treatment of neuropathic pain. International journal of pharmaceutical compounding, 12(3), 182–190.
  6. Brown, S., Erickson, B., Muller, G., Bryant-Snure, S. J., & Mestayer, R. F., III (2010). Compounded analgesic therapy for disorders of movement: arthritis, neuropathic pain, and postpolio syndrome. International journal of pharmaceutical compounding, 14(3), 182–192.
  7. Shakshuki, A., & Agu, R. U. (2019). Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?. International journal of pharmaceutical compounding, 23(6), 496–503.
  8. Elbeddini, A., Tanvir, A., Yilmaz, O., Rahman, Y., & Mongon, R. (2024). Assessing the efficacy of topical formulations in diabetic neuropathy: a narrative review. Journal of diabetes and metabolic disorders, 23(2), 1613–1620. https://doi.org/10.1007/s40200-024-01459-7
  9. Martin, C. J., Alcock, N., Hiom, S., & Birchall, J. C. (2017). Development and Evaluation of Topical Gabapentin Formulations. Pharmaceutics, 9(3), 31. https://doi.org/10.3390/pharmaceutics9030031
  10. Faghihi, G., Mohammadian, P., Abtahi-Naeini, B., Akbari, M., Sabzghabaee, A. M., & Mortazavi, M. (2024). Effectiveness of topical gabapentin cream in treating pruritus in dialysis patients: A randomized controlled trial. Hemodialysis international. International Symposium on Home Hemodialysis, 28(4), 429–434. https://doi.org/10.1111/hdi.13175
  11. Aquino, T. M. O., Luchangco, K. A. C., Sanchez, E. V., & Verallo-Rowell, V. M. (2020). A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus. International journal of dermatology, 59(8), 955–961. https://doi.org/10.1111/ijd.14953
  12. Saki, N., Vahedi, S., Parvizi, M. M., Shafie’ei, M., Hosseini, S. A., & Ahramiyanpour, N. (2022). Topical gabapentin 10% in the treatment of epidermolysis bullosa pruritus: A pilot, double-blind, split-site, randomized controlled trial. Dermatologic therapy, 35(10), e15767. https://doi.org/10.1111/dth.15767
  13. Boardman, L. A., Cooper, A. S., Blais, L. R., & Raker, C. A. (2008). Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstetrics and gynecology, 112(3), 579–585. https://doi.org/10.1097/AOG.0b013e3181827c77
  14. Ergisi, M., Law, A., Chaudhari, N., Tsatsari, S., Lawson, K., & Jenner, C. (2023). Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis. Frontiers in pain research (Lausanne, Switzerland), 4, 1159268. https://doi.org/10.3389/fpain.2023.1159268
  15. Yasaei R, Katta S, Patel P, et al. Gabapentin. [Updated 2024 Feb 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493228/
  16. Haddadi, S., Marzban, S., Parvizi, A., Nemati, S., Chohdari, A., Atrkar Roshan, Z., & Ramezani, H. (2020). Effects of Gabapentin Suspension and Rectal Acetaminophen on Postoperative Pain of Adenotonsillectomy in Children. Iranian journal of otorhinolaryngology, 32(111), 197–205. https://doi.org/10.22038/ijorl.2020.38811.2283
  17. Soliman II, Afify EA, Al Shobragi G. Evaluation of extemporaneous pediatric gabapentin suspension prepared from gabapentin capsules. Latin American Journal of Pharmacy. 2014; 33(5):746±52.
  18. Nahata M. C. (1999). Development of two stable oral suspensions for gabapentin. Pediatric neurology, 20(3), 195–197. https://doi.org/10.1016/s0887-8994(98)00134-9

Poproś o wycenę

Sprzedaż Apteczna
+48 12 656 54 37
+48 601 390 607
+48 604 566 836
+48 538 810 690

Sprzedaż Hurt
+48 12 33 43 508

Przedstawiciel Farmaceutyczno-Medyczny
łódzkie / dolnośląskie

Michał Stegliński
michal.steglinski@galfarm.pl
608 830 113

Przedstawiciel Farmaceutyczno-Medyczny
śląskie / opolskie

Barbara Nagórzańska
barbara.nagorzanska@galfarm.pl
606 742 603

Przedstawiciel Farmaceutyczno-Medyczny
wielkopolskie / zachodniopomorskie / lubuskie

Joanna Podgórna
joanna.podgorna@galfarm.pl
606 742 673

Przedstawiciel Farmaceutyczno-Medyczny
małopolskie / podkarpackie

Piotr Kozłowski
piotr.kozlowski@galfarm.pl
662 429 981

Przedstawiciel Farmaceutyczno-Medyczny
mazowieckie / warmińsko-mazurskie / podlaskie

Krzysztof Dzierżek
krzysztof.dzierzek@galfarm.pl
696 837 904

Przedstawiciel Farmaceutyczno-Medyczny
świętokrzyskie / lubelskie

Małgorzata Filipek
malgorzata.filipek@galfarm.pl
606 742 753

Przedstawiciel Farmaceutyczno-Medyczny
kujawsko-pomorskie / pomorskie

Przemysław Sztanga
przemyslaw.sztanga@galfarm.pl
662 068 289